이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab

2026년 11월 2일 업데이트: ImmunoGenesis

A Phase 1/2 Immunotherapy Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab in Patients With Advanced Solid Malignancies

The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

Tumor hypoxia can lead to poor effector T-cell penetration and immunosuppressive signaling via myeloid-derived suppressor cells, myofibroblasts, and regulatory T-cells. Disruption of these hypoxic regions within the tumor microenvironment by the hypoxia-directed cytotoxic agent evofosfamide may enhance the ability of immune checkpoint inhibitors to reject otherwise resistant solid tumors. The hypothesis tested in this study is that evofosfamide, by specifically targeting the hypoxic tumor microenvironment, may enhance the anti-tumor effects of the immune checkpoint inhibitors zalifrelimab (anti-CTLA-4) and balstilimab (anti-PD-1) in select tumors that are generally resistant to therapy.

In the Phase 1 dose escalation part of the study, the maximum tolerated dose (or maximum allowable dose) of evofosfamide in combination with zalifrelimab and balstilimab will be determined. A recommended Phase 2 dose (RP2D) will be determined based on safety and the totality of data.

The Phase 2 dose expansion part of the study will evaluate the Phase 2 dose of the triplet combination in 3 cohorts: 1) patients with locally advanced or metastatic castration-resistant prostate cancer; 2) patients with locally advanced or metastatic pancreatic cancer; and 3) patients with locally advanced or metastatic HPV-negative SCCHN. Each cohort expansion will be carried out independently.

연구 유형

중재적

등록 (추정된)

71

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Texas
      • Houston, Texas, 미국, 77030
        • MD Anderson Cancer Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Histologically confirmed locally advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, or HPV-negative SCCHN for which no other lines of standard therapy with demonstrated clinical benefit are available or appropriate as treatment.

  2. Appropriate to enter a clinical trial with a minimum estimated life expectancy of at least 3 months.

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  4. Measurable disease as defined by RECIST 1.1. Patients with castration-resistant prostate cancer can have measurable or evaluable disease per PCWG3 criteria. Patients with evaluable disease must have documented evidence of PD as defined by any of the following:

    • PSA progression: minimum of 2 rising values (3 measurements) obtained a minimum of 7 days apart with the last result being at least ≥4.0 ng/mL.
    • New or increasing non-bone disease per RECIST 1.1 criteria.
    • Positive bone scan with 2 or more new lesions (PCWG3).
  5. Adequate bone marrow function as defined by the following laboratory test results obtained within 7 days of Cycle 1 Day 1:

    • White blood cell count ≥2500 cells/mm3.
    • Absolute neutrophil count ≥1500 cells/mm3.
    • Absolute lymphocyte count >500 cells/mm3.
    • Hemoglobin ≥9 g/dL.
    • Platelets ≥75,000 cells/mm3.
  6. Adequate liver function as defined by the following laboratory test results obtained within 7 days of Cycle 1 Day 1:

    • Bilirubin ≤1.5 × institutional ULN; for patients with known Gilbert's syndrome, ≤3 × institutional ULN.
    • Aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT) ≤3 × institutional ULN; if liver metastases are present, then ≤5 × ULN is allowed.
  7. At least 3 weeks from previous cytotoxic chemotherapy or radiation therapy and at least 5 half-lives or 6 weeks, whichever is shorter, from targeted or biologic therapy with the exception of CTLA-4, PD-1, or PD-L1 blocking antibodies for which only a 2 week interval is required. Patients with prostate cancer, unless they have undergone prior orchiectomy, may continue to receive androgen deprivation therapy, anti-androgen therapy, or therapy that interferes with androgenic stimulation.

  8. All patients must be willing to undergo a biopsy to provide a new tumor sample within 14 days of Cycle 1 Day 1. Patients who are unable to undergo a biopsy at screening must submit archival tumor tissue retrieved within the last 6 calendar months. Patients must also consent to undergo a biopsy between Day 15 of Cycle 2 and Day 8 of Cycle 3 in those subjects which it is clinically safe and attainable. A biopsy is not required for participants with metastatic prostate cancer with bone-only disease or inaccessible soft tissue lesions.

  9. Calculated creatinine clearance ≥ 60 mL/min (by the Cockcroft Gault formula) within 7 days of Cycle 1 Day 1

Exclusion Criteria:

  1. A history of currently active/uncontrolled autoimmune diseases or disorders, including inflammatory bowel disease (including Crohn's disease and ulcerative colitis), rheumatoid arthritis, systemic sclerosis (scleroderma), systemic lupus erythematosus, or autoimmune vasculitis (eg, Wegener's granulomatosis).
  2. Patients with prior history of any Grade 3 or Grade 4 AEs from anti-CTLA-4, anti-PD-1/PD-L1, or anti-CTLA-4 and anti-PD-1/PD-L-1 combination therapy.
  3. History of acute diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, abdominal carcinomatosis, or other known risk factors for bowel perforation.
  4. Patients on long-term systemic steroids (>10 mg daily prednisone equivalent initiated >2 weeks prior to study enrollment). Inhaled or topical steroids are permitted in the absence of active autoimmune disease.
  5. Any underlying medical or psychiatric condition, which in the opinion of the investigator, will make the administration of study treatment hazardous or obscure the interpretation of AEs, e.g., a condition associated with frequent diarrhea or chronic skin conditions, recent surgery (within 30 days) or colonic biopsy from which the patient has not recovered, partial endocrine organ deficiencies, or substance abuse.
  6. Concomitant use of QT-prolonging drugs with a risk of causing Torsades de Pointes (TdP).
  7. History of risk factors for TdP, including family history of long QT syndrome.
  8. Corrected QT (QTc) interval of ≥470 msec calculated according to Fridericia's formula (QTc=QT/RR [0.33]).
  9. Sustained systolic blood pressure (BP) >140 mmHg or <90 mmHg and sustained diastolic BP >100 mmHg or <60 mmHg.
  10. Patients with newly diagnosed, uncontrolled and/or untreated cancer-related central nervous system disease. Patients with treated brain metastases that are radiographically or clinically stable for at least 2 weeks after therapy and have no evidence of cavitation or hemorrhage in the brain lesion(s) are eligible if they are asymptomatic and do not require corticosteroids (must have discontinued steroids at least 1 week prior to study enrollment).
  11. Uncontrolled intercurrent illness including, but not limited to, myocardial infarction within 6 months, unstable symptomatic ischemic heart disease, significant cardiac arrythmias, active uncontrolled infection requiring systemic therapy, or psychiatric illness/social situations that would limit compliance with study requirements.
  12. Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to study enrollment.
  13. Current evidence of active and uncontrolled infection, New York Heart Association Class III-IV chronic heart failure, documented Child's class B and C cirrhosis, active symptomatic pancreatitis, or uncontrolled medical disease which, in the opinion of the investigator, could compromise assessment of study treatment efficacy.
  14. Active human immunodeficiency virus infection (Exception: patients with well-controlled HIV [e.g., CD4 ≥ 350 cells/uL and undetectable viral load] who have been on an effective (drug, dosage, and schedule associated with reduction and control of the viral load) antiretroviral therapy (ART) for ≥ 4 weeks are eligible). Patients with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last 12 months are not eligible. Note: Drug-drug interactions with ART occur via many mechanisms, with cytochrome P450 CYP3A4-mediated interactions being the most common. Patients who are using concurrent strong or moderate CYP3A4 inhibitors (e.g., ritonavir, cobicistat) or strong or moderate CYP3A4 inducers must be switched to an alternate effective ART regimen ≥ 4 weeks before study enrollment or should be excluded from the study if their regimen cannot be altered.
  15. Active or chronic hepatitis B or C virus infection. Patients with a history of HCV infection must have completed curative antiviral treatment and must have a viral load below the limit of quantification. A patient who is HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution is eligible.
  16. Known hypersensitivity to any components of the study treatment or any of their excipients or analogs or drugs of similar chemical or biologic composition.
  17. Live vaccine within 4 weeks prior to study enrollment.
  18. Concomitant therapy with interleukin-2, interferon, or other non-study immunotherapy agents, or immunosuppressive agents.
  19. Concomitant use of strong or moderate inhibitors or strong or moderate inducers of CYP3A4 within 14 days or 5 half-lives (whichever is longer) prior to study enrollment and for the duration of study treatment.
  20. Concomitant use of anti-cancer chemotherapy, radiotherapy, hormone therapy, or targeted therapy. Patients with prostate cancer may continue treatment with anti-androgen and bone targeted therapies (e.g., zoledronic acid and denosumab). Palliative radiotherapy to nontarget lesions is permitted.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Castration-resistant prostate cancer

Evofosfamide + zalifrelimab + balstilimab

Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.

Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.

Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.

실험적: Pancreatic cancer

Evofosfamide + zalifrelimab + balstilimab

Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.

Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.

Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.

실험적: Human papilloma virus-negative squamous cell carcinoma of the head and neck

Evofosfamide + zalifrelimab + balstilimab

Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.

Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.

Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
용량 제한 독성을 포함한 이상반응의 발생률 및 심각도
기간: 12개월
12개월

2차 결과 측정

결과 측정
기간
전반적인 생존
기간: 12 개월
12 개월
심각한 부작용, 중단 및 사망
기간: 12개월
12개월
RECIST 1.1 및 iRECIST에 따른 무진행 생존율
기간: 12개월
12개월
RECIST 1.1 및 iRECIST 기준(또는 전립선암의 경우 PCWG3/RECIST)에 따른 객관적 반응률
기간: 12개월
12개월
RECIST 1.1 및 iRECIST에 따른 응답 기간
기간: 12개월
12개월
Evofosfamide, Br-IPM, balstilimab 및 zalifrelimab에 대한 농도-시간 곡선하 면적(AUC)을 포함한 약동학 매개변수
기간: 12개월
12개월
Evofosfamide, Br-IPM, balstilimab 및 zalifrelimab에 대한 Cmax를 포함한 약동학적 매개변수
기간: 12개월
12개월
Evofosfamide, Br-IPM, balstilimab 및 zalifrelimab에 대한 t1/2를 포함한 약동학적 매개변수
기간: 12개월
12개월
Zalifrelimab 및 balstilimab의 항 약물 항체 검출
기간: 12개월
12개월

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 1월 8일

기본 완료 (추정된)

2027년 10월 1일

연구 완료 (추정된)

2028년 1월 1일

연구 등록 날짜

최초 제출

2025년 1월 9일

QC 기준을 충족하는 최초 제출

2025년 1월 15일

처음 게시됨 (실제)

2025년 1월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • EVO-011

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

IPD 계획 설명

Availability of this study's data will later be determined according to ImmunoGenesis commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, ImmunoGenesis commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. Interested researchers should contact ImmunoGenesis patient-level data and supporting documents from clinical studies to conduct research.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .